Literature DB >> 26045800

ING4 enhances paclitaxel's effect on colorectal cancer growth in vitro and in vivo.

Liyu Cao1, Shunhua Chen2, Cong Zhang2, Cong Chen2, Nana Lu3, Yan Jiang2, Yongping Cai2, Yu Yin2, Jianming Xu4.   

Abstract

Inhibitor of growth 4 (ING4) is a tumor suppressor that can inhibit cell growth and induce apoptosis. ING4 expression levels show negative correlation with the clinical stage, histological grade, and lymph node metastasis of colorectal cancer. Further insights are needed to analyze the effect of adenovirus-mediated ING4 on colorectal cancer cell growth and the response to paclitaxel treatment. In this study, we found adenovirus-mediated ING4 expression reduced proliferation and enhanced apoptosis in the SW1116 cells. p-Stat3 and Ki-67 expression significantly decreased in the SW1116 cells treated with Ad-ING4, PTX, or Ad-ING4+PTX compared with those treated with PBS or Ad-GFP both in vitro and in vivo (P<0.05). In animal experiments, the mice treated with Ad-ING4, PTX, or Ad-ING4+PTX exhibited significantly inhibited growth of SW1116 xenografts compared with those treated with PBS or Ad-GFP (P<0.05) and the combination (Ad-ING4+PTX) treatment exhibited the highest inhibition. Our results highlight that Ad-ING4 significantly inhibits growth and induces apoptosis in SW1116 colorectal cancer cells and suppresses tumor growth in SW1116 xenografts by downregulating p-Stat3 and Ki-67 expression. A combination of Ad-ING4 and PTX exhibits the highest inhibition, indicating that ING4 enhances sensitivity to chemotherapy.

Entities:  

Keywords:  Colorectal cancer; adenovirus; inhibitor of growth family; paclitaxel; signal transducers and activators of transcription

Mesh:

Substances:

Year:  2015        PMID: 26045800      PMCID: PMC4440109     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  36 in total

Review 1.  Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers.

Authors:  Zhaohui Peng
Journal:  Hum Gene Ther       Date:  2005-09       Impact factor: 5.695

2.  Nuclear localization signal of ING4 plays a key role in its binding to p53.

Authors:  Xin Zhang; Ke-Sheng Wang; Zhi-Qin Wang; Lu-Sheng Xu; Qing-Wan Wang; Fei Chen; Dong-Zhi Wei; Ze-Guang Han
Journal:  Biochem Biophys Res Commun       Date:  2005-06-17       Impact factor: 3.575

3.  Stat3 as an oncogene.

Authors:  J F Bromberg; M H Wrzeszczynska; G Devgan; Y Zhao; R G Pestell; C Albanese; J E Darnell
Journal:  Cell       Date:  1999-08-06       Impact factor: 41.582

4.  A simplified system for generating recombinant adenoviruses.

Authors:  T C He; S Zhou; L T da Costa; J Yu; K W Kinzler; B Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

5.  Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors.

Authors:  T Kusaba; T Nakayama; K Yamazumi; Y Yakata; A Yoshizaki; T Nagayasu; I Sekine
Journal:  J Clin Pathol       Date:  2005-08       Impact factor: 3.411

Review 6.  The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis.

Authors:  Daniel J Brat; Anita C Bellail; Erwin G Van Meir
Journal:  Neuro Oncol       Date:  2005-04       Impact factor: 12.300

Review 7.  Targeting Stat3 in cancer therapy.

Authors:  Naijie Jing; David J Tweardy
Journal:  Anticancer Drugs       Date:  2005-07       Impact factor: 2.248

8.  Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells.

Authors:  Quan Lin; Raymond Lai; Lucian R Chirieac; Changping Li; Vilmos A Thomazy; Ioannis Grammatikakis; George Z Rassidakis; Wei Zhang; Yasushi Fujio; Keita Kunisada; Stanley R Hamilton; Hesham M Amin
Journal:  Am J Pathol       Date:  2005-10       Impact factor: 4.307

9.  ING tumor suppressor proteins are critical regulators of chromatin acetylation required for genome expression and perpetuation.

Authors:  Yannick Doyon; Christelle Cayrou; Mukta Ullah; Anne-Julie Landry; Valérie Côté; William Selleck; William S Lane; Song Tan; Xiang-Jiao Yang; Jacques Côté
Journal:  Mol Cell       Date:  2006-01-06       Impact factor: 17.970

10.  Phylogenetic analysis of the ING family of PHD finger proteins.

Authors:  Gordon H Y He; Caren C Helbing; Mary J Wagner; Christoph W Sensen; Karl Riabowol
Journal:  Mol Biol Evol       Date:  2004-09-08       Impact factor: 16.240

View more
  6 in total

1.  Identification of the inhibitor of growth protein 4 (ING4) as a potential target in prostate cancer therapy.

Authors:  Aymen Shatnawi; Sridhar A Malkaram; Tamer Fandy; Efrosini Tsouko
Journal:  Mol Cell Biochem       Date:  2019-11-27       Impact factor: 3.396

Review 2.  Inhibitor of growth-4 is a potential target for cancer therapy.

Authors:  Shuping Yuan; Jianhua Jin; Juanjuan Shi; Yongzhong Hou
Journal:  Tumour Biol       Date:  2016-01-23

3.  ING4 expressing oncolytic vaccinia virus promotes anti-tumor efficiency and synergizes with gemcitabine in pancreatic cancer.

Authors:  Yinfang Wu; Xiaozhou Mou; Shibing Wang; Xing-E Liu; Xiaodong Sun
Journal:  Oncotarget       Date:  2017-09-20

4.  Efficacy of combining ING4 and TRAIL genes in cancer-targeting gene virotherapy strategy: first evidence in preclinical hepatocellular carcinoma.

Authors:  A Galal El-Shemi; A Mohammed Ashshi; E Oh; B-K Jung; M Basalamah; A Alsaegh; C-O Yun
Journal:  Gene Ther       Date:  2017-09-19       Impact factor: 5.250

5.  Effect of bevacizumab on expression level of GLI1 and ING4 in colon cancer animal model.

Authors:  Bing Suo; Caiyu Wu; Fen Mei
Journal:  Oncol Lett       Date:  2020-05-28       Impact factor: 2.967

Review 6.  The essential role of tumor suppressor gene ING4 in various human cancers and non-neoplastic disorders.

Authors:  Yang Du; Yan Cheng; Guanfang Su
Journal:  Biosci Rep       Date:  2019-01-30       Impact factor: 3.840

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.